AKAN Quote, Financials, Valuation and Earnings

Iovance Biotherapeutics, Inc. has a net margin of -- compared to Akanda Corp.'s net margin of -135.28%. Akanda Corp.'s return on equity of -389.63% beat Iovance Biotherapeutics, Inc.'s return on equity of -54.43%.

Akanda Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Iovance Biotherapeutics, Inc. has an analysts' consensus of $8.25 which suggests that it could grow by 275%. Given that Iovance Biotherapeutics, Inc. has higher upside potential than Akanda Corp., analysts believe Iovance Biotherapeutics, Inc. is more attractive than Akanda Corp..

Akanda Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Iovance Biotherapeutics, Inc. has a beta of 0.827, suggesting its less volatile than the S&P 500 by 17.288%.

Akanda Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Iovance Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akanda Corp. pays -- of its earnings as a dividend. Iovance Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

Akanda Corp. quarterly revenues are --, which are smaller than Iovance Biotherapeutics, Inc. quarterly revenues of $67.5M. Akanda Corp.'s net income of -- is lower than Iovance Biotherapeutics, Inc.'s net income of -$91.3M. Notably, Akanda Corp.'s price-to-earnings ratio is -- while Iovance Biotherapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akanda Corp. is 1.77x versus 2.91x for Iovance Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Kiniksa Pharmaceuticals International Plc has a net margin of -- compared to Akanda Corp.'s net margin of 10.19%. Akanda Corp.'s return on equity of -389.63% beat Kiniksa Pharmaceuticals International Plc's return on equity of 7.6%.

Akanda Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Kiniksa Pharmaceuticals International Plc has an analysts' consensus of $54.00 which suggests that it could grow by 31.74%. Given that Kiniksa Pharmaceuticals International Plc has higher upside potential than Akanda Corp., analysts believe Kiniksa Pharmaceuticals International Plc is more attractive than Akanda Corp..

Akanda Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Kiniksa Pharmaceuticals International Plc has a beta of 0.017, suggesting its less volatile than the S&P 500 by 98.312%.

Akanda Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kiniksa Pharmaceuticals International Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akanda Corp. pays -- of its earnings as a dividend. Kiniksa Pharmaceuticals International Plc pays out -- of its earnings as a dividend.

Akanda Corp. quarterly revenues are --, which are smaller than Kiniksa Pharmaceuticals International Plc quarterly revenues of $180.9M. Akanda Corp.'s net income of -- is lower than Kiniksa Pharmaceuticals International Plc's net income of $18.4M. Notably, Akanda Corp.'s price-to-earnings ratio is -- while Kiniksa Pharmaceuticals International Plc's PE ratio is 91.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akanda Corp. is 1.77x versus 5.25x for Kiniksa Pharmaceuticals International Plc. Usually stocks with elevated PS ratios are considered overvalued.

Travere Therapeutics, Inc. has a net margin of -- compared to Akanda Corp.'s net margin of 15.59%. Akanda Corp.'s return on equity of -389.63% beat Travere Therapeutics, Inc.'s return on equity of -263.9%.

Akanda Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Travere Therapeutics, Inc. has an analysts' consensus of $41.5000 which suggests that it could grow by 19.08%. Given that Travere Therapeutics, Inc. has higher upside potential than Akanda Corp., analysts believe Travere Therapeutics, Inc. is more attractive than Akanda Corp..

Akanda Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Travere Therapeutics, Inc. has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.435%.

Akanda Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Travere Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akanda Corp. pays -- of its earnings as a dividend. Travere Therapeutics, Inc. pays out -- of its earnings as a dividend.

Akanda Corp. quarterly revenues are --, which are smaller than Travere Therapeutics, Inc. quarterly revenues of $164.9M. Akanda Corp.'s net income of -- is lower than Travere Therapeutics, Inc.'s net income of $25.7M. Notably, Akanda Corp.'s price-to-earnings ratio is -- while Travere Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akanda Corp. is 1.77x versus 7.26x for Travere Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Xenetic Biosciences, Inc. has a net margin of -- compared to Akanda Corp.'s net margin of -49.65%. Akanda Corp.'s return on equity of -389.63% beat Xenetic Biosciences, Inc.'s return on equity of -59.39%.

Akanda Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Xenetic Biosciences, Inc. has an analysts' consensus of -- which suggests that it could grow by 1552.89%. Given that Xenetic Biosciences, Inc. has higher upside potential than Akanda Corp., analysts believe Xenetic Biosciences, Inc. is more attractive than Akanda Corp..

Akanda Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Xenetic Biosciences, Inc. has a beta of 2.398, suggesting its more volatile than the S&P 500 by 139.837%.

Akanda Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xenetic Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akanda Corp. pays -- of its earnings as a dividend. Xenetic Biosciences, Inc. pays out -- of its earnings as a dividend.

Akanda Corp. quarterly revenues are --, which are smaller than Xenetic Biosciences, Inc. quarterly revenues of $1M. Akanda Corp.'s net income of -- is lower than Xenetic Biosciences, Inc.'s net income of -$509.9K. Notably, Akanda Corp.'s price-to-earnings ratio is -- while Xenetic Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akanda Corp. is 1.77x versus 1.31x for Xenetic Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.